PURPOSE: The purpose of this study is to identify the effect of HIV status on outcome of treatment for squamous-cell carcinoma of the anal canal. METHODS: A retrospective review was performed on all patients with squamous-cell carcinoma of the anal canal treated at a single academic institution between January 1996 and December 2006. RESULTS: Our search identified 87 (21 HIV-positive) patients who had invasive squamous-cell cancer. The median follow-up was 38 months. Eighty-five percent of HIV-negative patients and 81 percent of HIV-positive were identified as complete responders at 6 weeks after completion of combined modality therapy. Eight percent of HIV-negative and 29 percent of HIV-positive patients developed recurrent disease after 6 months (P = 0.0009). Overall survival for HIV-negative and HIV-positive patients was 71 percent and 73 percent, respectively. CONCLUSIONS: HIV-positive patients respond equally to combined modality therapy but have recurrences more frequently than patients who are HIV negative. Overall survival in these two groups is equivalent.
PURPOSE: The purpose of this study is to identify the effect of HIV status on outcome of treatment for squamous-cell carcinoma of the anal canal. METHODS: A retrospective review was performed on all patients with squamous-cell carcinoma of the anal canal treated at a single academic institution between January 1996 and December 2006. RESULTS: Our search identified 87 (21 HIV-positive) patients who had invasive squamous-cell cancer. The median follow-up was 38 months. Eighty-five percent of HIV-negative patients and 81 percent of HIV-positive were identified as complete responders at 6 weeks after completion of combined modality therapy. Eight percent of HIV-negative and 29 percent of HIV-positive patients developed recurrent disease after 6 months (P = 0.0009). Overall survival for HIV-negative and HIV-positive patients was 71 percent and 73 percent, respectively. CONCLUSIONS: HIV-positive patients respond equally to combined modality therapy but have recurrences more frequently than patients who are HIV negative. Overall survival in these two groups is equivalent.
Authors: Emmanouil P Pappou; Jonathan T Magruder; Tao Fu; Caitlin W Hicks; Joseph M Herman; Sandy Fang; Elizabeth C Wick; Bashar Safar; Susan L Gearhart; Jonathan E Efron Journal: World J Surg Date: 2018-03 Impact factor: 3.352
Authors: Bernhard Fankhaenel; Joerg Zimmer; Dorothea Bleyl; Eric Puffer; Andreas Schreiber; Thomas Kittner; Helmut Witzigmann; Sigmar Stelzner Journal: Int J Colorectal Dis Date: 2019-10-22 Impact factor: 2.571
Authors: Ira L Leeds; Hasan Alturki; Joseph K Canner; Eric B Schneider; Jonathan E Efron; Elizabeth C Wick; Susan L Gearhart; Bashar Safar; Sandy H Fang Journal: World J Surg Oncol Date: 2016-08-05 Impact factor: 2.754